RedHill Biopharma (RDHL) Capital Expenditures (2012 - 2022)
RedHill Biopharma's (RDHL) quarterly Capital Expenditures came in at -$22000.0 in Q3 2022, down 4.76% year-over-year from -$23100.0 in Q3 2021, and up 86.5% quarter-over-quarter from -$163000.0 in Q2 2022.
Powered by 
Analysis
RedHill Biopharma (RDHL) Capital Expenditures (2012 - 2022) Analysis & Trends
RedHill Biopharma (RDHL) has reported Capital Expenditures for 11 consecutive years, with -$22000.0 the latest figure, recorded in Q3 2022.
- On a quarterly basis, Capital Expenditures fell 4.76% year-over-year to -$22000.0 in Q3 2022; TTM through Dec 2022 was -$198000.0, a 72.17% decrease from a year earlier, with the FY2025 full-year figure at -$5000.0, up 44.44% from the prior year.
- Capital Expenditures was -$22000.0 for Q3 2022 at RedHill Biopharma, up from -$163000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at -$1000.0 in Q3 2019 and troughed at -$242000.0 in Q1 2020.
- A 5-year average of -$51631.6 and a median of -$20000.0 in 2020 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures soared 98.04% in 2018 and tumbled 16500.0% in 2020, its largest moves.
- Over 5 years, Capital Expenditures stood at -$5000.0 in 2018, then slumped by 560.0% to -$33000.0 in 2019, then tumbled by 48.48% to -$49000.0 in 2020, then surged by 93.88% to -$3000.0 in 2021, then sank by 633.33% to -$22000.0 in 2022.
- The last three Capital Expenditures figures came in at -$22000.0 (Q3 2022), -$163000.0 (Q2 2022), and -$13000.0 (Q1 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 104.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 52.80 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | -36.19 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 30.70 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 77.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -27.87 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 3.05 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 8.59 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | -22,000.00 |
| Jun 30, 2022 | -163,000.00 |
| Mar 31, 2022 | -13,000.00 |
| Dec 31, 2021 | -3,000.00 |
| Sep 30, 2021 | -21,000.00 |
| Jun 30, 2021 | -3,000.00 |
| Mar 31, 2021 | -88,000.00 |
| Dec 31, 2020 | -49,000.00 |
| Sep 30, 2020 | -166,000.00 |
| Jun 30, 2020 | -20,000.00 |
| Mar 31, 2020 | -242,000.00 |
| Dec 31, 2019 | -33,000.00 |
| Sep 30, 2019 | -1,000.00 |
| Jun 30, 2019 | -128,000.00 |
| Mar 31, 2019 | -6,000.00 |
| Dec 31, 2018 | -5,000.00 |
| Sep 30, 2018 | -3,000.00 |
| Jun 30, 2018 | -2,000.00 |
| Mar 31, 2018 | -13,000.00 |
| Dec 31, 2017 | -3,000.00 |